This article has Open Peer Review reports available.
MicroRNA-26b inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting USP9X
© Shen et al.; licensee BioMed Central Ltd. 2014
Received: 1 December 2013
Accepted: 20 May 2014
Published: 2 June 2014
Metastasis is responsible for the rapid recurrence and poor survival of malignancies. Epithelial-mesenchymal transition (EMT) has a critical role in metastasis. Increasing evidence indicates that EMT can be regulated by microRNAs (miRNAs). The aim of this study was to investigate the role of miR-26b in modulating epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma (HCC), as well as to identify its underlying mechanism of action.
The expression level of miR-26b was assessed in multiple HCC cell lines (HepG2, MHCC97H, Hep3B, MHCC97L, HCCC9810, BEL-7402, Huh7 and QGY-7703), as well as in liver tissue from patients with HCC. Follow-up studies examined the effects of a miR-26b mimic (increased expression) and a miR-26b inhibitor (decreased expression) on markers of EMT, wound healing and cell migration. The molecular target of miR-26b was also identified using a computer algorithm and confirmed experimentally.
MiR-26b expression was decreased in HCC cell lines and was inversely correlated with the grade of HCC. Increased expression of miR-26b inhibited the migration and invasiveness of HCC cell lines, which was accompanied by decreased expression of the epithelial marker E-cadherin and increased expression of the mesenchymal marker vimentin, at both the mRNA and protein expression levels. A binding site for miR-26b was theoretically identified in the 3′UTR of USP9X. Further studies revealed that overexpression of miR-26b repressed the endogenous level of USP9X protein expression. Overexpression of miR-26b also repressed Smad4 expression, whereas its inhibition elevated Smad4 expression.
Taken together, our results indicate that miR-26b were inhibited in HCC. In HCC cell lines, miR-26b targeted the 3′UTR of USP9X, which in turn affects EMT through Smad4 and the TGF-β signaling pathway. Our analysis of clinical HCC samples verifies that miR-26b also targets USP9X expression to inhibit the EMT of hepatocytes. Thus, miR-26b may have some effects on the EMT of HCC cells.
Hepatocellular carcinoma (HCC) is a common and aggressive cancer, with an increasing incidence globally, especially in China . Despite technical advances and improved surgical treatment, the rate of tumor recurrence and metastasis after curative resection remains high [2, 3]. Exploring the molecular mechanisms underlying the initiation, progression and metastasis of HCC is vital as it may provide new therapeutic targets, leading to improvements in the long-term survival of patients with HCC . Although the genetic events responsible for HCC initiation and progression are not clear, they involve at least three carcinogenic pathways: the p53, NF-κB and transforming growth factor (TGF-β) signaling pathways [5–7].
The TGF-β signaling pathway is particularly pertinent to the current study, as it is known to play a central role in tumorigenesis and tumor progression by regulating many critical cellular processes, including cell proliferation, apoptosis and epithelial-mesenchymal transition (EMT) . Furthermore, TGF-β has been shown to have a central role in the growth of hepatocytes . With regard to the progression of HCC, it has previously been shown in HCC cell lines, such as Hep3B, HepG2, PLC/PRF5, that TGF-β signaling triggers EMT , characterized by lower E-cadherin expression and high vimentin expression in vitro . There is also convincing evidence that TGF-β signaling can induce EMT in mouse hepatocytes in vitro . Subsequent studies revealed the mechanism to be the result of TGF-β-induced activation of the SNAIL transcription factor, a key mediator of EMT, and repression of epithelial markers, such as E-cadherin . The Smad protein family is known to play a key role in the TGF-β signaling, particularly Smad4, the ubiquitination of which is a key regulatory step in TGF-β signaling . Indeed, loss of inactivation of Smad4 has been linked with multiple cancers, including pancreatic, colorectal, and gastrointestinal cancers [14–16].
Protein ubiquitination is a reversible, post-translational modification that regulates various aspects of cellular physiology, including protein degradation and cell signaling . Deubiquitinating enzymes (DUBs) are ubiquitin-specific proteases that can cleave ubiquitin from its substrate . Among approximately 100 DUBs encoded by the human genome, the ubiquitin-specific peptidase 9, X-linked (USP9X/FAM), is implicated in multiple physiological pathways . USP9X has been shown to regulate multiple cellular functions, and increased expression of USP9X in tumors is significantly associated with poor prognosis for patients with multiple myeloma . Numerous targets of USP9X have been identified so far, including AF-6, β -catenin, NUAK1, MARK4, ErbB2, EFA6, Smad4, Mcl1, ASK1 and survivin .
Recently, microRNA (miRNA) mimics and anti-sense microRNAs have been focused on as potential therapeutics for HCC due to their stability and predominant uptake by the liver . MiRNAs bind to the 3′ untranslated region (UTR) to suppress translation of target genes . An increasing body of evidence indicates that miR-26b is downregulated in breast cancer , nasopharyngeal carcinoma , colorectal cancer  and in hepatocellular carcinoma . miR-26b has also been associated with hepatocellular carcinoma development and worst outcome after liver cancer therapy [28, 29]. However, to date, the role of miR-26b in hepatocellular carcinoma tumorigenesis and metastasis is incompletely understood.
The goal of the current study was to investigate the role of miR-26b in HCC. We found that the expression of miR-26b was decreased in HCC cells and tissues from HCC patients with advanced grades of disease. Mimicry of miR-26b in Huh7 and Hep3B cells resulted in diminished proliferation, migration and invasiveness, accompanied by a low expression level of USP9X. Further, we identified USP9X as a target of miR-26b, which was confirmed by luciferase analysis, Western blotting examination. Our study provides evidence that miR-26b acts as tumor suppressor in HCC, and is an important negative regulator of USP9X.
Human HCC tissue
Liver samples collected from patients with HCC and control liver samples were collected for research purposes, with the patient’s prior consent and approval from the Second Affiliated Hospital of Guangzhou Medical University and the Guangzhou Women and Children’s Medical Center.
The following human HCC cell lines were studied: HepG2, MHCC97H, Hep3B, MHCC97L, HCCC9810, BEL-7402, Huh7 and QGY-7703. All cells were grown in DMEM medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (HyClone, Logan, Utah, USA) and 1% penicillin/streptomycin.
Manipulation of miR-26b expression levels
The miR-26b mimics, negative control (micrON™ miRNA Mimic Negative Controls and micrOFF™ miRNA Inhibitor Negtive Controls) and miR-26b inhibitor were purchased from RiboBio (Guangzhou, Guangdong, China). The final concentrations of transfection is 20 nM.
Construction of USP9X plasmids
The region of the human USP9X 3′-UTR, from 1041 to 1486 were generated by PCR amplification from DNA isolated from HepG2 cells. The amplified fragment was then cloned into the pEGFP-C1 (Clontech, Mountain View, CA, USA) and pGL3 vector (Promega, Madison, Wisconsin, USA). The primers selected were as follows: USP9X -3′UTR-GFP-up, 5′ CCGCTCGAGCCAGTGACGTGGAAGTCATC 3′; USP9X -3′UTR-GFP-dn, 5′ CGGGGTACCCACCACAGGACAAAAAGTTCTTC 3′; USP9X -3′UTR-luc-up, 5′ CGGGGTACCCCAGTGACGTGGAAGTCATC 3′; and USP9X -3′UTR-luc-dn, 5′ CCGCTCGAGCACCACAGGACAAAAAGTTCTTC 3′.
Transfection of the plasmids, miRNA and miRNA inhibitor was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, USA) according to the manufacturer’s instructions.
Cells were harvested in sampling buffer (62.5 mmol/L Tris-HCl [pH 6.8], 10% glycerol, 2% SDS) and heated for 5 min at 100°C. The concentration of extracted proteins was determined by the Bradford assay using a commercial kit (Bio-Rad, Berkeley, CA, USA ). Equal quantities of protein were separated by electrophoresis on 12% SDS/polyacrylamide gels and transferred onto polyvinylidene difluoride membranes (Roche, Indianapolis, Indiana, USA). The membranes were then probed with rabbit primary antibodies against USP9X(#5751S), E-cadherin(#9835S), Vimentin(#3877P) and GFP(#2955S) (Cell Signaling Technology, Danvers, Massachusetts, USA). The expression level of the target protein was determined with horseradish peroxidase-conjugated anti-rabbit/anti-mouse IgG (#31212/ #31160) and enhanced chemiluminescence (Pierce, Rockford, Illinois, USA), according to the manufacturer’s protocol. The membranes were stripped and reprobed with an anti-β-actin mouse monoclonal antibody (BOSTER, Wuhan, Hubei, China) to serve as a loading control.
RNA extraction and real-time quantitative PCR
Total miRNA from cultured cells and fresh surgical HCC tissues was extracted using the mirVana miRNA Isolation Kit (# AM1561, Ambion, Austin, Texas, USA), according to the manufacturer’s protocol. Complimentary DNA was synthesized from 5 ng of total RNA using the TaqMan miRNA reverse transcription kit (Applied Biosystems, Foster City, California, USA). The expression level of miR-26b was quantified using a miRNA-specific TaqMan MiRNA Assay Kit (Applied Biosystems), using an Applied Biosystems 7500 Sequence Detection system. The expression level of miRNA was defined based on the threshold cycle (Ct), and relative expression levels were calculated using the 2-ΔΔCt method, using the expression level of the U6 small nuclear RNA as a reference gene.
Cell migration assay
The migration assay was performed using a transwell chamber, consisting of 8 mm membrane filter inserts (Corning, New York, USA) coated with Matrigel (BD Biosciences, California, USA). Briefly, cells were trypsinized and suspended in serum-free medium. Next, 1.5 × 105 cells were added to the upper chamber, and the lower chamber was filled with medium containing 10% FBS. After 36 h incubation, cells that had invaded the lower chamber were fixed with 4% paraformaldehyde, stained with hematoxylin, and counted using a microscope.
Wound healing assay
The wound healing assay was performed using HepG2 and Huh7 cells. Cells were trypsinized and seeded in equal numbers into 6-well tissue culture plates, and allowed to grow until confluent (approximately 24 h). Following serum starvation for 24 h, an artificial homogenous wound (‘scratch’) was created onto the cell monolayer with a sterile 100 μL tip. After scratching, the cells were washed with serum-free medium, complete media was added, and microscopic images (20× magnification) of the cells were collected at 0, 12, and 24 h.
3D morphogenesis assay
Twenty-four-well dishes were coated with Growth Factor Reduced Matrigel (BD Biosciences, California, USA), and covered with growth medium supplemented with 2% Matrigel. Cells were trypsinized and seeded at a density of 104 cells/well. The medium was replaced with 2% Matrigel every 3 to 4 days and microscopic images (20× magnification) were captured at 2 day intervals for 2 to 3 weeks.
Dual luciferase reporter assay
Cells (3.5 × 104) were seeded in triplicate in 24-well plates and allowed to settle over 24 h. Next, 100 ng of pGL3-USP9X-3′UTR (wt/mut), or control-luciferase plasmid plus 1 ng of pRL-TK renilla plasmid (# E2810. Promega, Madison, Wisconsin, USA) were transfected into the cells using Lipofectamine 2000 (Invitrogen Co., Carlsbad, California, USA), according to the manufacturer’s recommendations. Luciferase and renilla signals were measured 48 h after transfection using the Dual Luciferase Reporter Assay Kit (Promega, Madison, Wisconsin, USA), according to the manufacturer’s protocol. Three independent experiments were performed and the data are presented as the mean ± SD.
A two-tailed Student’s t-test was used to evaluate the statistical significance of the differences between two groups of data in all pertinent experiments. A P-value less than 0.05 was considered to be statistically significant. All statistical analyses were performed using the SPSS 13.0 (IBM) statistical software package.
The microscopy we have used as:
Zeiss Axio Imager A1——Zeiss, Oberkochen, Germany
Zeiss Axiovert 40c——Zeiss, Oberkochen, Germany
Axiovert 200——Zeis, Oberkochen, Germany
MiR-26b downregulation correlates with progression of human hepatocellular carcinoma
MiR-26b suppresses the invasiveness of HCC cells
MiR-26b directly targets USP9X in HCC cells
To determine whether the miR-26b-induced downregulation of USP9X was mediated through the 3′UTR containing the miR-26b binding site, we subcloned the USP9X 3′UTR fragment into PEGFP-C1 and pGL3 dual luciferase reporter vectors. As our Western blotting analysis showed, elevating the endogenous levels of miR-26b only decreased expression of the GFP vector containing the USP9X with 3′UTR, but had no effect on GFP-r-tubulin expression (Figure 4B), suggesting that miR-26b specifically affected the 3′UTR of USP9X. Furthermore, western blotting and immunofluorescence staining results showed that the abundance of Smad4 was significantly increased when miR-26b was suppressed, and was decreased in the presence of elevated miR-26b expression (Figure 2B and 4C). Moreover, a consistent and dose-dependent reduction in luciferase activity was observed following miR-26b transfection in both Huh7 and Hep3B cells, whereas the repressive effect of miR-26b on the luciferase activity of USP9X 3′UTR was abolished by miR-26b inhibition (Figure 4D), and point mutations in the tentative miR-26b-binding seed region in USP9X 3′-UTR abrogated the suppressive effect of USP9X mediated by miR-26b (Figure 4E). Last but not the least, real-time PCR result showed that the expression level of SNAIL mRNA was significantly decreased in either miR-26b orUSP9X siRNA over-expressed HCC cells (Additional file 3: Figure S3). Collectively, these results demonstrate that miR-26b directly acts through the 3′UTR of USP9X in HCC cells.
USP9X plays an important role in miR-26b suppressed invasiveness of HCC cells
In order to confirm the link between miR-26b, USP9X and EMT in HCC, we studied the expression level of miR-26b, USP9X and E-cadherin in primary liver tumor tissue from patients with HCC. For this analysis, five freshly prepared normal human liver samples were compared with nine samples from patients with HCC. As shown in Figure 5B, miR-26b expression and E-cadherin protein expression were markedly downregulated in HCC tissue, but the expression level of USP9X was higher, compared with normal human liver tissue. Furthermore, linear regression analysis showed that miR-26b expression positively correlated with E-cadherin expression (r = 0.838, P < 0.05), and negatively correlated with USP9X (r = –0.714, P < 0.05).
The goal of the current study was to investigate the role of miR-26b in EMT and the metastasis of HCC. During EMT, polarized epithelial cells acquire a mesenchymal phenotype; in the context of cancer, this transformation is associated with tumor invasiveness, metastasis, and resistance to chemotherapy [5, 7, 23, 24]. A number of cytokines and growth factors are known to be induced during EMT, which amplifies the EMT program and promotes cell migration. These factors include the cytokines TGF-β, Wnt, Notch ligands, interleukin-like EMT-inducers , hepatocyte growth factor , epidermal growth factor  and platelet-derived growth factor .
The levels of transcription factors driving EMT are controlled by miRNAs . While miR-26a and miR-26b have been reported can regulate the NF-κB, TGF-β signal pathways . And miR-26b was downregulated in hepatic tumors, as compared to paired noncancerous tissue . Similarly, patients whose tumors had low miR-26 expression had a shorter survival time, although they were more likely to respond to interferon-α than patients whose tumors had high miR-26 expression . Several studies have confirmed that miR-26a and miR-26b are downregulated in NPC (nasopharyngeal carcinoma) , CRC (colorectal cancer) . Mechanistically, miR-26 is thought to be growth suppressive; it has been shown that miR-26b acts through c-myc to block the G1/S transition .
The role of TGFβ in EMT, tumor invasiveness and metastasis has been firmly established by in vitro and in vivo studies [8, 32]. Interestingly, TGF-β-induced activation of Smad complexes (particularly Smad3 and 4) have been shown to play a crucial role during the induction of EMT [32–35]. Ubiquitination of Smad4 is known to be a key regulatory step in the TGF-β signaling pathway, leading to the identification of the DUB USP9X as a required factor for Smad activity [30, 32, 37]. In mammalian cells and Xenopus embryos, USP9X sustains both TGF-β and BMP signaling by deubiquitinating Smad4 and counteracting the inhibitory activity of Ecto/Tif1-c . Here, we identified USP9X as a novel target of miR-26b, such that miR-26b interacted with the 3′-UTR of USP9X to suppress its expression, with resultant effects on Smad4 expression and the TGF-β signaling pathway.
There is usually an inverse relationship between the expression level of a particular miRNA and its target . Our conclusion that USP9X is a novel target gene of miR-26b is supported by several pieces of evidence: (1) the 3′-UTR of both human and murine USP9X mRNA contains a putative miR-26b binding site; (2) miR-26b suppresses the activity of a luciferase reporter gene fused with the 3′-UTR of USP9X mRNA, which is dependent on the miR-26b binding sequence; (3) miR-26b represses the endogenous expression of human/murine USP9X at both the mRNA and protein level. Our follow-up studies indicated that the ability of miR-26b to inhibit cancer cell invasion was mediated through its ability to downregulate USP9X expression.
USP9X was previously reported to regulate Smad4 transcriptional activity positively, thus we hypothesized that decreased USP9X expression would attenuate Smad4 function and TGF-β responsiveness in HCC cell lines . Our data demonstrate that transfection with a miR-26b mimic decreased Smad4 expression in both Huh7 and Hep3B cells, while transfection of a miR-26b inhibitor upregulated Smad4 expression. These results suggest that the effect of miR-26b on HCC cells may be mediated through Smad4, with a resultant effect on the TGF-β signaling pathway.
In conclusion, we have identified miR-26b as a tumor suppressive miRNA in human HCC, which acts at least in part through the repression of USP9X. Mechanistically, our data suggests a model in which miR-26b binds to the 3′-UTR of USP9X to inhibit its expression. Decreased USP9X expression leads to an attenuation of Smad4 function and TGF-β responsiveness, inhibiting the EMT and growth of HCC cells. Our data suggests that miR-26b may play some roles in the EMT of HCC cells, although future studies are required to confirm this.
We gratefully acknowledge Bo Chen (The Second affiliated Hospital of Guangzhou Medical University, Guangzhou, PR China) for helpful discussions and technical assistance. We also thank Pro. Libing Song who provided medical writing services on behalf of Cancer Center of Sun Yat-Sen University. This work was supported by grants from National Science Foundation of China (No.81101317) and The Science and Technology Department of Guangzhou (No. 201300000173).
- El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007, 132 (7): 2557-2576. 10.1053/j.gastro.2007.04.061.View ArticlePubMedGoogle Scholar
- Gao J, Inagaki Y, Song P, Qu X, Kokudo N, Tang W: Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. Pharmacol Res. 2012, 65 (1): 23-30. 10.1016/j.phrs.2011.11.011.View ArticlePubMedGoogle Scholar
- Kubo S, Takemura S, Sakata C, Urata Y, Uenishi T: Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus. Liver Cancer. 2013, 2 (1): 40-46. 10.1159/000346214.View ArticlePubMedPubMed CentralGoogle Scholar
- Aravalli RN, Steer CJ, Cressman EN: Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008, 48 (6): 2047-2063. 10.1002/hep.22580.View ArticlePubMedGoogle Scholar
- Heldin C-H, Vanlandewijck M, Moustakas A: Regulation of EMT by TGFb in cancer. FEBS Lett. 2012, 586 (14): 1959-1970. 10.1016/j.febslet.2012.02.037.View ArticlePubMedGoogle Scholar
- Jing Y, Han Z, Liu Y, Sun K, Zhang S, Jiang G, Li R, Gao L, Zhao X, Wu D, Cai X, Wu M, Wei L: Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. PLoS ONE. 2012, 7 (8): e43272-10.1371/journal.pone.0043272.View ArticlePubMedPubMed CentralGoogle Scholar
- Zheng X, Vittar NB, Gai X, Fernandez-Barrena MG, Moser CD, Hu C, Almada LL, McCleary-Wheeler AL, Elsawa SF, Vrabel AM, Shire AM, Comba A, Thorgeirsson SS, Kim Y, Liu Q, Fernandez-Zapico ME, Roberts LR: The transcription factor GLI1 mediates TGFb1 driven EMT in hepatocellular carcinoma via a SNAI1-dependent mechanism. PLoS ONE. 2012, 7 (11): e49581-10.1371/journal.pone.0049581.View ArticlePubMedPubMed CentralGoogle Scholar
- Mima K, Hayashi H, Kuroki H, Nakagawa S, Okabe H, Chikamoto A, Watanabe M, Beppu T, Baba H: Epithelial-mesenchymal transition expression profiles as a prognostic factor for disease-free survival in hepatocellular carcinoma: clinical significance oftransforming growth factor-β signaling. Oncol Lett. 2013, 5 (1): 149-154.PubMedGoogle Scholar
- Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA: Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer. 2012, 24 (1): 12-26.Google Scholar
- Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H, Watanabe M, Beppu T, Tamada M, Nagano O, Saya H, Baba H: CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res. 2012, 72 (13): 3414-3423. 10.1158/0008-5472.CAN-12-0299.View ArticlePubMedGoogle Scholar
- Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Matsumoto K, Saijo N, Kudo M, Nishio K: Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther. 2011, 10 (1): 169-177. 10.1158/1535-7163.MCT-10-0544.View ArticlePubMedGoogle Scholar
- Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA: Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 2009, 119 (6): 1438-1449. 10.1172/JCI38019.View ArticlePubMedPubMed CentralGoogle Scholar
- Lahsnig C, Mikula M, Petz M, Zulehner G, Schneller D, Van Zijl F, Huber H, Csiszar A, Beug H, Mikulits W: ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression. Oncogen. 2009, 28 (5): 638-650. 10.1038/onc.2008.418.View ArticleGoogle Scholar
- Le Gendre O, Sookdeo A, Duliepre SA, Utter M, Frias M, Foster DA: Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality inSMAD4-defective pancreatic cancer cells. Mol Cancer Res. 2013, 11 (5): 474-481. 10.1158/1541-7786.MCR-12-0679.View ArticlePubMedGoogle Scholar
- Liu L, Nie J, Chen L, Dong G, Du X, Wu X, Tang Y, Han W: The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression. PLoS ONE. 2013, 8 (2): e55532-10.1371/journal.pone.0055532.View ArticlePubMedPubMed CentralGoogle Scholar
- Schwenter F, Faughnan ME, Gradinger AB, Berk T, Gryfe R, Pollett A, Cohen Z, Gallinger S, Durno C: Juvenile polyposis, hereditary hemorrhagic telangiectasia, and early onset colorectal cancer in patients with SMAD4 mutation. J Gastroenterol. 2012, 47 (7): 795-804. 10.1007/s00535-012-0545-8.View ArticlePubMedGoogle Scholar
- Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y: Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009, 15 (3): 195-206. 10.1016/j.ccr.2009.01.023.View ArticlePubMedGoogle Scholar
- Imamura T, Oshima Y, Hikita A: Regulation of TGF-β family signaling by ubiquitination and deubiquitination. J Biochem. 2013, 154 (6): 481-489. 10.1093/jb/mvt097.View ArticlePubMedGoogle Scholar
- Yang CC, Wolf DA: Inflamed snail speeds metastasis. Cancer Cell. 2009, 15 (5): 355-357. 10.1016/j.ccr.2009.04.003.View ArticlePubMedGoogle Scholar
- Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O’Rourke K, Bazan F, Eastham-Anderson J, Yue P, Dornan D, Huang DC, Dixit VM: Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2010, 463 (7277): 103-107. 10.1038/nature08646.View ArticlePubMedGoogle Scholar
- Han KJ, Foster DG, Zhang NY, Kanisha K, Dzieciatkowska M, Sclafani RA, Hansen KC, Peng J, Liu CW: Ubiquitin-specific protease 9x deubiquitinates and stabilizes the spinal muscular atrophy protein-survival motor neuron. J Biol Chem. 2012, 287 (52): 43741-43752. 10.1074/jbc.M112.372318.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang Z, Liu ZB, Ren WM, Ye XG, Zhang YY: The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. Int J Mol Med. 2012, 30 (4): 856-862.PubMedGoogle Scholar
- Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, Sphyris N, Shariati M, Kumar SV, Battula VL, Herschkowitz JI, Guerra R, Chang JT, Miura N, Rosen JM, Mani SA: FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res. 2013, 73 (6): 1981-1992. 10.1158/0008-5472.CAN-12-2962.View ArticlePubMedPubMed CentralGoogle Scholar
- Li J, Li X, Kong X, Luo Q, Zhang J, Fang L: MiRNA-26b inhibits cellular proliferation by targeting CDK8 in breast cancer. Int J Clin Exp Med. 2014, 7 (3): 558-565.PubMedPubMed CentralGoogle Scholar
- Ji Y, He Y, Liu L, Zhong X: MiRNA-26b regulates the expression of cyclooxygenase-2 in desferrioxamine-treated CNE cells. FEBS Lett. 2010, 584 (5): 961-967. 10.1016/j.febslet.2010.01.036.View ArticlePubMedGoogle Scholar
- Zhang C, Tong J, Huang G: Nicotinamide phosphoribosyl transferase (Nampt) is a target of microRNA-26b incolorectal cancer cells. PLoS One. 2013, 8 (7): e69963-10.1371/journal.pone.0069963.View ArticlePubMedPubMed CentralGoogle Scholar
- Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, Bolondi L, Negrini M: microRNA involvement in hepatocellular carcinoma. J Cell Mol Med. 2008, 12 (6A): 2189-2204. 10.1111/j.1582-4934.2008.00533.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW: microRNA expression, survival and response to interforn in liver cancer. N Engl J Med. 2009, 361 (15): 1437-1447. 10.1056/NEJMoa0901282.View ArticlePubMedPubMed CentralGoogle Scholar
- Palumbo T, Faucz FR, Azevedo M, Xekouki P, Iliopoulos D, Stratakis CA: Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway. Oncogene. 2013, 32 (13): 1651-1659. 10.1038/onc.2012.190.View ArticlePubMedGoogle Scholar
- Le Goff C, Mahaut C, Abhyankar A, Le Goff W, Serre V, Afenjar A, Destrée A, Di Rocco M, Héron D, Jacquemont S, Marlin S, Simon M, Tolmie J, Verloes A, Casanova JL, Munnich A, Cormier-Daire V: Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre syndrome. Nat Genet. 2011, 44 (1): 85-88. 10.1038/ng.1016.View ArticlePubMedGoogle Scholar
- Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R, Aust D, Rümmele P, Knösel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, Li A, Morgan R, Knight S, Yu J, Stegeman S, Collier LS, Ten Hoeve JJ, De Ridder J, Klein AP, Goggins M, Hruban RH, Chang DK, Biankin AV, Grimmond SM, Wessels LF, et al: The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature. 2012, 486 (7402): 266-270.PubMedPubMed CentralGoogle Scholar
- Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M, Martello G, Stinchfield MJ, Soligo S, Morsut L, Inui M, Moro S, Modena N, Argenton F, Newfeld SJ, Piccolo S: FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell. 2009, 136 (1): 123-135. 10.1016/j.cell.2008.10.051.View ArticlePubMedGoogle Scholar
- Xia H, Ooi LL, Hui KM: MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013, 58 (2): 629-641. 10.1002/hep.26369.View ArticlePubMedGoogle Scholar
- Zhao N, Wang R, Zhou L, Zhu Y, Gong J, Zhuang SM: MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol Cancer. 2014, 13 (2): 35-46.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang JR, Zeng C, Zhuang SM: MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res. 2012, 40 (10): 4615-4625. 10.1093/nar/gkr1278.View ArticlePubMedGoogle Scholar
- Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF, Li XP: MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011, 71 (1): 225-233. 10.1158/0008-5472.CAN-10-1850.View ArticlePubMedGoogle Scholar
- Ma YL, Zhang P, Wang F, Moyer MP, Yang JJ, Liu ZH, Peng JY, Chen HQ, Zhou YK, Liu WJ, Qin HL: Human embryonic stem cells and metastatic colorectal cancer cells shared the common endogenous human microRNA-26b. J Cell Mol Med. 2011, 15 (9): 1941-1954. 10.1111/j.1582-4934.2010.01170.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Théard D, Labarrade F, Partisani M, Milanini J, Sakagami H, Fon EA, Wood SA, Franco M, Luton F: USP9x-mediated deubiquitination of EFA6 regulates de novo tight junction assembly. EMBO J. 2010, 29 (9): 1499-1509. 10.1038/emboj.2010.46.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/393/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.